Upload
others
View
9
Download
2
Embed Size (px)
Citation preview
Deterioration of subclinical atherosclerosis
markers during and after pegylated interferon
and ribavirin treatment for chronic hepatitis C
Alexandra Alexopoulou1, George Georgiopoulos2, Sofia
Pouriki1, Ilianna Mani1, Larisa Vasilieva1, Angeliki Laina2,
Dimitrios Zampetas1, Kimon Stamatelopoulos1, Spyros P
Dourakis1
12nd Department of Internal Medicine and Research Laboratory, Medical
School, National and Kapodistrian University of Athens, Hippokration
Hospital, Athens, Greece
2Vascular Laboratory, Department of Clinical Therapeutics, National and
Kapodistrian University of Athens, Alexandra University Hospital, 80 V.
Sofias Str, 11528 Athens, Greece
Conflict of interest
No conflict of interest to declare
Introduction
Interferon↑ adhesion of leukocytes to the
endothelium
↑ chemotaxis of platelets
Vascular damage : endothelial injury, micro-
infractions
Karbasi-Afshar R et al, Iranian journal of medical sciences. 2014;39(3):238-46.
Introduction
Myocardial infraction
Interferon
Chronic hepatitis C
Arrythmias
Cardiomyopathy Pulmonary hypertension
Karbasi-Afshar R et al, Iranian journal of medical sciences 2014, 39(3):238-46.
Salman H et al, Cancer 1999, 85(6):1375-9.
Evaluation of possible changes in vascular
markers of subclinical atherosclerosis during
and after PR treatment for CHC.
Aim
Methods
24 consecutive patients with CHC
• non smokers
• without diabetes or arterial hypertension
• 58.3%♂
• Mean age 43.1 (13.3)
24 healthy controls
Evaluation of
vascular markers in 3
visits
Before treatment
(T1)End of treatment
(T2)24 weeks post treatment
(T3)
Peg INF
Ribavirin
Liver disease
58.3%
14
37.5%
9
4.2%
1
25%
cirrhotics
Genotype
Result of treatment
83.3%
20
16.7%
4
Methods
1. Anthropometric measurements:
- Height
- Weight
- Body Mass Index
- Waist and hip circumference
2. Vascular tests :
- Flow-mediated, endothelium-dependent vasodilation – FMD
- Carotid-femoral pulse wave velocity (PWV)
- Pulse wave analysis (PWA)
- Peripheral and central systolic (SBP) and diastolic blood pressure
(DBP)
- Intima-media thickness (IMT) of the carotid artery
For each patient data that were collected, include :
Vascular tests were conducted in a fixed order by the
same operator who was blinded to the medical history
of the participants
DT
PWV = D/T
Measurement of pulse transit time and the distance travelled between the
common carotid artery and the common femoral artery (Complior, Artech
Medical, Pantin, France)
Carotid-femoral pulse wave velocity (PWV)(m/s)
Pulse wave analysis (PWA) at radial artery
Central systolic blood pressure (c_sbp)
Central diastolic blood pressure (c_dbp)
Αugmentation Ιndex, ΑΙx
P1
P2
Augmentation index =
(P2 – P1)/Pulse pressure x 100
Change
Between the
First and
second
Inflection point
Pre
ssu
re (
mm
Hg
)Time (milliseconds)
Pu
lse
pre
ssu
re
Estimation of aortic pressure waveforms and reflected waves
(SphygmoCor System (AtCor Medical Pty Ltd, Sydney, Australia)
Flow-mediated, endothelium-dependent vasodilation – FMD
A high-resolution ultrasound machine is used to estimate
increase in arterial blood flow as a result of reactive
hyperemia.(Vivid 7 Pro, General Electric, USA)
Intima-media thickness (IMT) of the carotid artery
Measurement of intima-media thickness and estimation of atherosclerosis
using B-MODE Ultrasound (14 MHZ Multi-frequency Linear Array Probe, Vivid 7
Pro, General Electric)
Parameters expressed as
Mean, (SD) or Median (IQR)Controls (n=24) HCV (n=24) p-value
Age (years) 47.3 (7.51) 43.1(13.3) 0.184
Gender, male n (%) 14 (58.3) 14 (58.3) 1.000
BMI (kg/m2) 28.5 (3.47) 26.2 (4.62) 0.129
Hyperlipidemia, n(%) 12 (50) 0 (0) <0.001
Waist, (cm) 98 (87-104) 96 (84-104) 0.545
Cirrhosis, n(%) - 6 (25%) NA
Sustained virological response,
n(%)
- 20 (83.3) NA
Genotype 1, n(%) - 14 (58.3%) NA
Genotype 3, n(%) - 9 (37.5%) NA
ALT (IU/L) 19.5 (11-30) 70 (52-124) <0.0001
SBP (mmHg) 120.3 (16.8) 122.3 (17.3) 0.693
DBP (mmHg) 76.3 (10.7) 74.5 (10.6) 0.572
Aortic SBP (mmHg) 112 (17.7) 112 (17.8) 1.00
Aortic DBP (mmHg) 77.9 (11.1) 75.6 (10.7) 0.503
Augmentation index at 75 bpm (%) 21.5 (16-29) 18.5 (11-27) 0.261
PWV (m/s) 9.05 (7.8-9.95) 7.8 (6.5-8.85) 0.075
FMD(%) 2.38 (0.781-4.76) 2.63 (2.09-6.07) 0.286
Combined IMT (mm) 0.081 (0.066-0.522) 0.068 (0.060-0.080) 0.055
Common carotid IMT (mm) 0.072 (0.055-0.439) 0.065 (0.057-0.075) 0.292
Carotid bifurcation IMT (mm) 0.099 (0.069-0.527) 0.073 (0.055-0.096) 0.028
Internal carotid IMT (mm) 0.077 (0.060-0.505) 0.065 (0.054.-0.087) 0.105
Baseline descriptive characteristics of the study population as allocated in
two groups of interest
T1 T2 T3Interaction
T1 vs T2
Interaction
T1 vs T3
mean±SD or
median(IQR)
mean±SD or
median(IQR)
mean±SD or
median(IQR)
Coefficient
(95%CIs)p value
Coefficient
(95%CIs)p value
SBP
CHC 122.3±17.3 126.7±16.5 123.9±14.5 0.784
(-11.141 to
12.7)
0.897
5.25
(-4.415 to
14.9)
0.287Controls 120.3±16.8 110.3±16.3 119.8±14.7
Aortic SBP
CHC 122.3 ± 17.3 116.3±15.5 114.8±14.3 0.699
(-10.192 to
11.6)
0.900
6.42
(-2.719 to
15.6)
0.169Controls 112± 17.7 103.3±17.8 112±13.9
Longitudinal changes in hemodynamic parameters of interest in our study
population across the pre-specified time points of assessment
Augmentation index
CHC 18.5 (11 to 27) 18 (14.5 to 26) 22.5 (14 to 29) 2.23
(-2.815 to
7.28)
0.3863.67
0.130 to 7.22)0.042
Controls21.5
(16 to 29)27 (17 to 33)
25.5
(22.5 to 31.5)
Pulse Wave Velocity
CHC7.8
(6.55 to 8.85)7.28
(6.78 to 7.9)
7.75
(7.3 to 8.9)0.036
(-0.792 to
0.864)
0.932
0.645
(0.037 to
1.25)
0.037
Controls9.05
(7.8 to 9.95)8.85
(7.65 to 9.55)
8.75
(7.75 to 9.2)
Flow Mediated Dilatation
CHC2.63
(2.09 to 6.07)
4.95
(3.92 to 7.11)
3.78
(1.26 to 7.49)-72%
(-92% to -2%)0.047
46.6%
(-79% to
601%)0.696
Controls2.38
(0.781 to 4.76)
3.13
(0.763 to 4.88)
4.88
(2.19 to 5.66)
Time to the beginning of the reflected wave
CHC149.5
(140 to 156)
145
(141 to 158)
144
(140 to 154) -2%
(-7% to 2%)0.351
-3%
(-6% to 0.3%) 0.071
Controls144
(130 to 148.5)
135
(126 to 151)
139.5
(132.5 to 144.5)
Longitudinal changes in vascular parameters of interest in our study population
across the pre-specified time points of assessment
T1 T2 T3Interaction
T1 vs T2
Interaction
T1 vs T3
mean±SD or
median(IQR)
mean±SD or
median(IQR)
mean±SD or
median(IQR)
Coefficient
(95%CIs)p value
Coefficient
(95%CIs)p value
Longitudinal changes in pulse wave velocity per group of
interest (CHC patients or healthy controls) across the follow
up
9.5
9
8.5
8
P = 0.932 P = 0.037
T1 T2 T3
7.5
7
Pu
lse w
ave v
elo
cit
y (
m/s
)
Controls CHC patients
20
15
P = 0.386 P = 0.042
T1 T2 T3
25
Controls CHC patients
Au
gm
en
tati
on
in
de
x (
%)
Longitudinal changes in augmentation index per group of
interest (CHC patients or healthy controls) across the follow
up
Study limitations
Small sample size
Short follow up period
Circulating markers of endothelial function were not
measured in the study and endothelial dysfunction was
evaluated solely by FMD.
Peg INF Ribavirin
+
Conclusions
Markers of subclinical
atherosclerosis deteriorate in
patients with CHC during PR. This
deterioration continues at least 6
months after stopping treatment.
Longitudinal changes in aortic diastolic blood pressure
(DBP) per group of interest (CHC patients or healthy
controls) across the follow up
Ao
rtic
dia
sto
lic b
loo
d p
lessu
re (
mm
Hg
)
P = 0.214 P = 0.003
85
80
75
70
65
T1 T2 T3
Controls HCV patients
Methods
Before visits, abstain of :
for 24 hours
for 12 hours
Vascular measurements were performed in every visit, as
described below
Blood pressure was recorded in each subject twice (1 minute
apart) by oscillometry using the automated Omron 705IT device
(Omron) after resting in the sitting position for 5 minutes
0.251 (0.228-0.388) 0.405 (0.238-0.472)
P = 0.017
Comparison of median max diameter of branchial artery after
reactive hyperemia before treatment and 24 weeks post
treatment
Before treatment 24 weeks post treatment
ma
x d
iam
ete
r o
f b
ran
ch
ial a
rte
ry a
fte
r
rea
cti
ve
hyp
ere
mia
, m
m
116.00 (101.00-124.00)112.00 (96.25-120.25)
P = 0.034
Comparison of median c_ sbp before treatment and 24 weeks
post treatment
Ce
ntr
al s
ys
tolic
blo
od
pre
ss
ure
(m
mH
g)
Before treatment 24 weeks post treatment
26.50 (18.00-36.00) 24.00 (15.75-31.25)
P = 0.044
Au
gm
en
tati
on
in
de
x (
Alx
, %
)Comparison of median Αugmentation index (AIx) before
treatment and 24 weeks post treatment
Before treatment 24 weeks post treatment
7.55 (7.07-9.20) 7.50 (6.55-8.47)
P = 0.028
Comparison of median PWVf before treatment and 24 weeks
post treatment
24 weeks post treatmentBefore treatment
7.75 (7.25-9.05) (7.27 (6.79-7.95)
P = 0.080
Comparison of median PWVf at the end of treatment and 24
weeks post treatmentP
uls
e W
ave
Ve
loc
ity F
em
ora
l (P
WV
f, m
/s)
End of treatment 24 weeks post treatment
Wa
ist
cir
cu
mfe
ren
ce
, c
mComparison of median waist circumference in HCV patients
before treatment and at the end of treatment
104.0 (92.5-107.0) 107 (98.0-112.0)
P = 0.023
Before treatment End of treatment
Beginning of therapy till 23 weeks post therapy
Parameter Adjusted Alteration (95% CI) P
Alx Alteration in systolic blood
pressure (F0,F3,F4), BMI
(F0,F3,F4), Age (F1), Gender
↑2.25% (0.972,3.53
)
0.002
24 weeks post treatment compared with end of treatment
PWV Alteration in systolic blood
pressure (F0,F3,F4), BMI
(F0,F3,F4), Age (F1), Gender,
cirrhosis
0.6m/s(0.122,1.06)
0.018
LINEAR MIXED MODELS – SVR patients (n=20)
specified time points of assessment
T1 T2 T3 Interaction T1 vs T2 Interaction T1 vs T3
mean±SD or
median(IQR)
mean±SD or
median(IQR)
mean±SD or
median(IQR)
Coefficient
(95%CIs)p value
Coefficient
(95%CIs)p value
SBP
CHC 122.3±17.3 126.7±16.5 123.9±14.5 0.784
(-11.141 to
12.7)
0.897
5.25
(-4.415 to
14.9)
0.287Controls 120.3±16.8 110.3±16.3 119.8±14.7
DBP
CHC 74.5 ± 10.6 75.8±8.47 73.5±10.2 3.84
(-2.812 to
10.5)
0.2587.67
(2.03 to 13.3)0.008
Controls 76.3±10.7 69.1±7.82 72.1 ±8.54
Aortic SBP
CHC 122.3 ± 17.3 116.3±15.5 114.8±14.3 0.699
(-10.192 to
11.6)
0.900
6.42
(-2.719 to
15.6)
0.169Controls 112± 17.7 103.3±17.8 112±13.9
Aortic DBP
CHC 75.6 ± 10.7 77±8.31 75.5±10.2 4.20
(-2.434 to
10.8)
0.2148.82
(2.93 to 14.7)0.003
Controls 77.9± 11.1 70.4±8.82 73.8±9.40
*Augmentation index
CHC 18.5 (11 to 27) 18 (14.5 to 26) 22.5 (14 to 29) 2.23
(-2.815 to
7.28)
0.3863.67
0.130 to 7.22)0.042
Controls21.5
(16 to 29)27 (17 to 33)
25.5
(22.5 to 31.5)
*Pulse Wave Velocity
CHC7.8
(6.55 to 8.85)7.28
(6.78 to 7.9)
7.75
(7.3 to 8.9)0.036
(-0.792 to
0.864)
0.9320.645
(0.037 to 1.25)0.037
Controls9.05
(7.8 to 9.95)8.85
(7.65 to 9.55)
8.75
(7.75 to 9.2)
*Flow Mediated Dilatation
CHC2.63
(2.09 to 6.07)
4.95
(3.92 to 7.11)
3.78
(1.26 to 7.49) -72%
(-92% to -2%)0.047
46.6%
(-79% to
601%)0.696
Controls2.38
(0.781 to 4.76)
3.13
(0.763 to 4.88)
4.88
(2.19 to 5.66)
Beginning of therapy till 23 weeks post therapy
Parameter Adjusted Alteration (95% CI) P
Alx Alteration in systolic blood pressure
(F0,F3,F4), BMI (F0,F3,F4), Age (F1),
Sex
↑1.52% (0.45, 2.55) 0.006
Alx Alteration in systolic blood pressure,
(F0,F3,F4), BMI (F0,F3,F4), Age (F1),
Sex, cirrhosis, genotype of HCV
↑4.2% (1.42,6.99) 0.005
Max diameter of
brachial artery
after reactive
hyperemia
Alteration in systolic blood pressure
(F0,F3,F4), BMI (F0,F3,F4), Age (F1),
Gender, cirrhosis, genotype of HCV ↓-0.05mm (-0.084, -0.017) 0.005
LINEAR MIXED MODELS(n=26)
25.78 (23.01-29.66) 25.15 (22.88-29.24)
P = 0.022
Comparison of median BMI in HCV patients before treatment
and at the end of treatmentB
od
y M
as
s In
de
x, B
MI k
g/
m2
Before treatment End of treatment
ΣΥΓΚΡΙΣΗ ΤΙΜΩΝ AIx ΠΡΙΝ ΤΗΝ ΕΝΑΡΞΗ ΤΗΣ ΘΕΡΑΠΕΙΑΣ
ΚΑΙ 24 ΕΒΔΟΜΑΔΕΣ ΜΕΤΑ ΤΗΝ ΟΛΟΚΛΗΡΩΣΗ ΘΕΡΑΠΕΙΑΣ
ΓΟΝΟΤΥΠΟΣ 1
23.00 (14.25-33.00) 22.00 (11.00-29.00)
P = 0.022
Au
gm
en
tati
on
in
de
x (
Alx
, %
)
ΣΥΓΚΡΙΣΗ ΔΙΑΜΕΣΩΝ ΟΡΩΝ ΤΙΜΩΝ AIX ΠΡΙΝ ΤΗΝ ΕΝΑΡΞΗ
ΤΗΣ ΘΕΡΑΠΕΙΑΣ ΚΑΙ 24 ΕΒΔΟΜΑΔΕΣ ΜΕΤΑ ΤΗΝ
ΟΛΟΚΛΗΡΩΣΗ ΘΕΡΑΠΕΙΑΣ
ΓΟΝΟΤΥΠΟΣ 3
20.00 (13.50-26.50) 15.50 (10.25-23.50
P=0.050
Au
gm
en
tati
on
in
de
x (
Alx
, %
)
ΣΥΓΚΡΙΣΗ ΤΙΜΩΝ ΜΕΓΙΣΤΗΣ ΔΙΑΜΕΤΡΟΥ ΤΟΥ ΑΓΓΕΙΟΥ ΜΕΤΑ ΤΗΝ
ΑΝΤΙΔΡΑΣΤΙΚΗ ΥΠΕΡΑΙΜΙΑ ΠΡΙΝ ΤΗΝ ΕΝΑΡΞΗ ΤΗΣ ΘΕΡΑΠΕΙΑΣ ΚΑΙ 24
ΕΒΔΟΜΑΔΕΣ ΜΕΤΑ ΤΗΝ ΟΛΟΚΛΗΡΩΣΗ ΘΕΡΑΠΕΙΑΣ
ΓΟΝΟΤΥΠΟΣ 1
0.247 (0.231-0.390) 0.410 (0.382-0.472)
P = 0.051